
I/We claim:

1. A compound of Formula (I):




Formula (I)

its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof; wherein,

ring A is selected from a group consisting of C_{6-10}aryl, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl, wherein, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S;

R_1 is independently selected from a group consisting of hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo, thioxo, -SO_2-, amino, hydrazino, formyl, C_{1-8}alkyl, C_{1-8}haloalkyl, C_{1-8}alkoxy, C_{1-8}haloalkoxy, C_{7-12}arylalkoxy, C_{3-8}cycloalkyl, C_{3-8}cycloalkyloxy, C_{6-10}aryl, C_{2-10}heterocyclyl, and C_{1-6}heteroaryl; wherein, C_{2-10}heterocyclyl, and C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, C_{7-12}arylalkoxy, C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and C_{3-8}cycloalkyl, is independently optionally substituted with one or more of the groups selected from C_{1-8} alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, oxo, C_{3-8} cycloalkyl, halogen, hydroxy, amino, or cyano;

ring B is 

;

Y is selected from a group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, C_{3-8}cycloalkyl, -CO, and -CO-C_{2-10}heterocyclyl; wherein C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and -CO-C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S;

wherein, C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and C_{3-8}cycloalkyl, is independently optionally substituted with one or more of the groups selected from C_{1-8} alkyl, oxo, C_{3-8} cycloalkyl, halogen, hydroxy or cyano;

Z is selected from a group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{7-12}-alkylaryl, C_{2-10}heterocyclyl, C_{7-12}-arylalkenyl, C_{2-12}-alkylheteroaryl, -CO-C_{7-12}alkylaryl, -CO-C_{7-12}alkenylaryl, -CONR$_6$-C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, -CO-C_{2-10}heterocyclyl, -NR$_6$-C_{6-10}aryl, -NR$_6$-C_{1-6}heteroaryl, -O-C_{6-10}aryl, -O-C_{1-6}heteroaryl, -CONR$_6$-C_{7-12}alkylaryl, -SO$_2$-C_{6-10}aryl, -SO$_2$-C_{7-12}alkylaryl, and -NR$_6$SO$_2$-C_{7-12}alkylaryl; wherein C_{2-10}heterocyclyl, C_{2-12}-alkylheteroaryl, C_{1-6}heteroaryl, -CO-C_{2-10}heterocyclyl, -NR$_6$-C_{1-6}heteroaryl, and -O-C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;


R_6 is hydrogen or C_{1-8} alkyl;

R_2 is selected from a group consisting of hydroxy, aniline, C_{6-10}aryl, amino C_{6-10}aryl, and amino C_{1-6}heteroaryl; wherein amino C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, aniline, C_{6-10}aryl, amino C_{6-10}aryl, and amino C_{1-6}heteroaryl, is independently optionally substituted with one or more of the groups selected from amino, C_{1-8}alkyl, halogen, hydroxy or cyano; and

n is 1 to 4.

2. The compound as claimed in claim 1, having the structure depicted in Formula (IA)



Formula (IA)

its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof;

wherein,

ring A is selected from a group consisting of C_{6-10}aryl, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl, wherein, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S;

R_1 is independently selected from a group consisting of hydrogen, halogen, oxo, C_{1-8}alkyl, C_{6-10}aryl, C_{2-10}heterocyclyl, and C_{3-6}heteroaryl; wherein C_{2-10}heterocyclyl and C_{3-6}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, C_{3-6}heteroaryl, and C_{2-10}heterocyclyl, is independently optionally substituted with one or more oxo or C_{1-8}alkyl;

Y is selected from a group consisting of C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and -CO; wherein C_{1-6}heteroaryl, and C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S; wherein, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl is independently optionally substituted with one or more oxo or C_{1-8} alkyl;

Z is selected from a group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{7-12}-alkylaryl, C_{2-10}heterocyclyl, -CO-C_{7-12}alkylaryl, -CO-C_{7-12}alkenylaryl, and C_{1-6}heteroaryl; wherein C_{2-10}heterocyclyl, and C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

R_2 is hydroxy or C_{6-10}aryl; wherein, C_{6-10}aryl, is substituted with amino; and n is 1 to 4.

3. The compound as claimed in claims 1 and 2, wherein, ring A is selected from a group consisting of C_{6-8} aryl, C_{3-5}heteroaryl, and C_{5-9}heterocyclyl, wherein, C_{3-5}heteroaryl, and C_{5-9}heterocyclyl has one or more heteroatoms selected from N, O or S;

R_1 is independently selected from a group consisting of hydrogen, halogen, oxo, C_{1-4}alkyl, C_{6-8}aryl, C_{5-9}heterocyclyl, and C_{3-5}heteroaryl; wherein C_{5-9}heterocyclyl and C_{3-5}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, C_{5-9}heterocyclyl and C_{3-5}heteroaryl is independently optionally substituted with one or more oxo or C_{1-4}alkyl;

Y is selected from a group consisting of C_{2-5}heteroaryl, and C_{5-9}heterocyclyl; wherein C_{2-5}heteroaryl, and C_{5-9}heterocyclyl has one or more heteroatoms selected from N, O or S, wherein, C_{2-5}heteroaryl, and C_{5-9}heterocyclyl is independently optionally substituted with one or more oxo or C_{1-4} alkyl;

Z is selected from a group consisting of C_{1-4}alkyl, C_{7-9}-alkylaryl, and -CO-C_{7-10}alkenylaryl;

R_2 is hydroxy or C_{6-8}aryl; wherein, C_{6-8}aryl is substituted with amino; and n is 1 to 4.

4. The compound as claimed in claims 1 to 3, selected from a group consisting of:

1. N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrobromide;

2. N-hydroxy-4-((4-((((1S,2R)-2-phenylcyclopropyl)amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide;

3. N-hydroxy-4-(3-(4-((((1R,2S)-2-(1-phenyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

4. N-hydroxy-4-(3-(4-((((1S,2R)-2-(1-phenyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

5. 4-((E)-3-(3-((((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)methyl) azetidin-1-yl)-3-oxoprop-1-en-1-yl)-N-hydroxybenzamide;

6. 4-((E)-3-(3-((((1S,2R)-2-(4-fluorophenyl)cyclopropyl)amino)methyl) azetidin-1-yl)-3-oxoprop-1-en-1-yl)-N-hydroxybenzamide;

7. N-hydroxy-4-(3-(4-((((1R,2S)-2-(4-(pyrimidin-5-yl)phenyl)cyclo propyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

8. N-hydroxy-4-(3-(4-((((1S,2R)-2-(4-(pyrimidin-5-yl)phenyl)cyclo propyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

9. N-hydroxy-4-(3-(4-((((1R,2S)-2-(1,3,3-trimethyl-2-oxoindolin-5-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

10. N-hydroxy-4-(3-(4-((((1S,2R)-2-(1,3,3-trimethyl-2-oxoindolin-5-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

11. N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl) piperidin-1-yl)methyl)benzamide;

12. N-hydroxy-4-((4-((((1S,2R)-2-phenylcyclopropyl)amino)methyl) piperidin-1-yl)methyl)benzamide;

13. N-hydroxy-4-(3-(4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl) piperidin-1-yl)propyl)benzamide;

14. N-hydroxy-4-(3-(4-((((1S,2R)-2-phenylcyclopropyl)amino)methyl) piperidin-1-yl)propyl)benzamide;

15. N-(2-aminophenyl)-4-(3-(4-((((1R,2S)-2-(4-fluorophenyl)cyclopropyl) amino)methyl)piperidin-1-yl)propyl)benzamide;

16. N-(2-aminophenyl)-4-(3-(4-((((1S,2R)-2-(4-fluorophenyl)cyclopropyl) amino)methyl)piperidin-1-yl)propyl)benzamide;

17. N-(2-aminophenyl)-4-(3-(4-((((1R,2S)-2-(1-isopropyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

18. N-(2-aminophenyl)-4-(3-(4-((((1S,2R)-2-(1-isopropyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

19. N-(2-aminophenyl)-4-((4-((((1R,2S)-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide;

20. N-(2-aminophenyl)-4-((4-((((1S,2R)-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide;

21. N-(2-aminophenyl)-4-((4-((((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzamide;

22. N-(2-aminophenyl)-4-((4-((((1S,2R)-2-(4-fluorophenyl)cyclopropyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzamide;

23. N-(2-aminophenyl)-4-(3-(4-((((1R,2S)-2-(1-phenyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

24. N-(2-aminophenyl)-4-(3-(4-((((1S,2R)-2-(1-phenyl-1H-pyrazol-4-yl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

25. N-(2-aminophenyl)-4-(3-(4-((((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

26. N-(2-aminophenyl)-4-(3-(4-((((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzamide;

27. N-(2-aminophenyl)-4-((4-((((1R,2S)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide;

28. N-(2-aminophenyl)-4-((4-((((1S,2R)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide;


29. N-(2-aminophenyl)-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzamide; and

30. N-(2-aminophenyl)-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide.

5. A process of preparation of compounds of Formula (I) as claimed in any one of the claims 1 to 4, the process comprising:

Step 1: reacting a compound 1 with an aldehyde or a ketone in a protic solvent to give an intermediate imine followed by reaction with a reducing agent to give an intermediate compound 2 or alternatively reacting compound 1 with an alkyl halide optionally in presence of a base to give an intermediate compound 2; and

Step 2: hydrolyzing the intermediate compound 2 with an inorganic base to result in the corresponding acid, followed by coupling the acid with the respective amine NH_2R_2 in the presence of an activating agent to yield the compound of Formula (I) or alternatively reacting the intermediate compound 2 with NH_2R_2 and an inorganic base to yield the compound of Formula (I),




Scheme 1

----- is ····· or ——

ring A is selected from a group consisting of C_{6-10}aryl, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl, wherein, C_{1-6}heteroaryl, and C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S;

R_1 is independently selected from a group consisting of hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo, thioxo, -SO_2-, amino, hydrazino, formyl, C_{1-8}alkyl, C_{1-8}haloalkyl, C_{1-8}alkoxy, C_{1-8}haloalkoxy, C_{7-12}arylalkoxy, C_{3-8}cycloalkyl, C_{3-8}cycloalkyloxy, C_{6-10}aryl, C_{2-10}heterocyclyl, and C_{1-6}heteroaryl; wherein, C_{2-10}heterocyclyl, and C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, C_{7-12}arylalkoxy, C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and C_{3-8}cycloalkyl, is independently optionally substituted with one or more of the groups selected from C_{1-8} alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, oxo, C_{3-8} cycloalkyl, halogen, hydroxy, amino, or cyano;

ring B is ;

Y is selected from a group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, C_{3-8}cycloalkyl, -CO, and -CO-C_{2-10}heterocyclyl; wherein C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and -CO-C_{2-10}heterocyclyl has one or more heteroatoms selected from N, O or S;

wherein, C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, C_{2-10}heterocyclyl, and C_{3-8}cycloalkyl, is independently optionally substituted with one or more of the groups selected from C_{1-8} alkyl, oxo, C_{3-8} cycloalkyl, halogen, hydroxy or cyano;

Z is selected from a group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{7-12}-alkylaryl, C_{2-10}heterocyclyl, C_{7-12}-arylalkenyl, C_{2-12}-alkylheteroaryl, -CO-C_{7-12}alkylaryl, -CO-C_{7-12}alkenylaryl, -CONR$_6$-C_{1-8}alkyl, C_{6-10}aryl, C_{1-6}heteroaryl, -CO-C_{2-10}heterocyclyl, -NR$_6$-C_{6-10}aryl, -NR$_6$-C_{1-6}heteroaryl, -O-C_{6-10}aryl, -O-C_{1-6}heteroaryl, -CONR$_6$-C_{7-12}alkylaryl, -SO$_2$-C_{6-10}aryl, -SO$_2$-C_{7-12}alkylaryl, and -NR$_6$SO$_2$-C_{7-12}alkylaryl; wherein C_{2-10}heterocyclyl, C_{2-12}-alkylheteroaryl, C_{1-6}heteroaryl, -CO-C_{2-10}heterocyclyl, -NR$_6$-C_{1-6}heteroaryl, and -O-C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

R$_6$ is hydrogen or C_{1-8} alkyl;

R$_2$ is selected from a group consisting of hydroxy, aniline, C_{6-10}aryl, amino C_{6-10}aryl, and amino C_{1-6}heteroaryl; wherein amino C_{1-6}heteroaryl has one or more heteroatoms selected from N, O or S;

wherein, aniline, C_{6-10}aryl, amino C_{6-10}aryl, and amino C_{1-6}heteroaryl, is independently optionally substituted with one or more of the groups selected from amino, C_{1-8}alkyl, halogen, hydroxy or cyano; and

n is 1 to 4.

6. The process as claimed in claim 5, wherein the activating agent is selected from EDCI. HCl (1(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), HOBt (1-hydroxybenzotriazole) or (1-propylphosphonic anhydride)T3P/triethylamine; the protic solvent is selected from methanol, ethanol, water, or combinations thereof; and the reducing agent is selected from sodium borohydride, lithium borohydride, aluminum borohydride, or combinations thereof.

7. The process as claimed in claim 5, wherein the base is selected from triethylamine, N, N-diisopropylethylamine, potassium carbonate, pyridine, or combinations thereof; and the inorganic base is selected from potassium carbonate, sodium carbonate, cesium carbonate, or combinations thereof.

8. A pharmaceutical composition comprising the compound of any one of the claims 1 to 4 and a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutically acceptable carrier.

9. The pharmaceutical composition as claimed in claim 8, wherein the composition is in a form selected from a group consisting of a tablet, capsule, powder, syrup, solution, aerosol and suspension.

10. Use of a pharmaceutical composition in the manufacture of a medicament for inhibiting HDAC enzymes, or LSD1 enzymes or both LSD1 enzymes and HDAC enzymes, or modulating MYC or coREST, in a subject in need thereof, the pharmaceutical composition comprising the compound as claimed in any one of the claims 1 to 4, optionally in combination with one or more other pharmaceutical formulations.

11. A pharmaceutical composition comprising a compound as claimed in any one of the claims 1 to 4, wherein the compound has enantiomeric excess of higher than 60%, preferably higher than 80%.

12. Use of the compound as claimed in any one of the claims 1 to 4 in the manufacture of a medicament for inhibiting HDAC enzymes, LSD1 enzymes, or both HDAC enzymes and LSD1 enzymes, or for modulating MYC or coREST in a cell, for treating a disease or a condition.

13. The use as claimed in claim 12, wherein the disease or the condition is selected from breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, rectal cancer, esophagus cancer, duodenal cancer, tongue cancer, pharyngeal cancer, brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, liver cancer, liver metastasis, kidney cancer, bile duct cancer, uterine body cancer, cervical cancer, ovarian cancer, urinary bladder, skin cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma and leukemia including acute myelogenous leukemia (AML),

chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), Myeloproliferative neoplasms (MPN), polycythemia vera (PV), myeloproliferative dysplastic syndrome, essential thrombocythemia (ET), essential thrombocytosis and myelofibrosis (MF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), cancers with specific mutations in the SWI/SNF complex, ARID1A, ARID1B, SMARCA4, SMARCA2, cancers with mutations in specific oncogenes, EGFR, KRAS, RET, cancers with differential expression of certain genes, LAPTM5, RNASE6, IL-16, APOBEC3 and TYROBP, depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic lateral sclerosis, Dementia with lewy bodies, Frontotemporal dementia or MYC amplified tumor.

14. Use of the compound of any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treating, preventing, modulating or ameliorating a disease or condition mediated by MYC or coREST or LSD1 or HDAC or both LSD1 and HDAC in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject, optionally wherein the medicament is to be administered with other clinically relevant immune modulator agents or other clinically relevant cytotoxic agents or non-cytotoxic agents.

15. The use as claimed in claim 14, wherein the other clinically relevant immunomodulator agents are selected from a group consisting of CD27, CD28, CD40, CD 122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1 and PD-L2.

16. Use of the compound as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for inhibiting both LSD1 and HDAC, or transcriptional cofactor in a cell in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject .

17. Use of the compound as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treating and/or preventing a disease or a condition mediated by both LSD1 and HDAC or a proliferative

disorder or cancer, wherein a therapeutically effective amount of the medicament is to be administered to a subject suffering from the disease or condition mediated by both LSD1 and HDAC or the proliferative disorder or cancer.

18. The use as claimed in claims 14, 16 and 17, wherein the disease or condition is selected from breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, rectal cancer, esophagus cancer, duodenal cancer, tongue cancer, pharyngeal cancer, brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, liver cancer, liver metastasis, kidney cancer, bile duct cancer, uterine body cancer, cervical cancer, ovarian cancer, urinary bladder, skin cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma and leukemia including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), Myeloproliferative neoplasms (MPN), polycythemia vera (PV), myeloproliferative dysplastic syndrome, essential thrombocythemia (ET), essential thrombocytosis and myelofibrosis (MF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), cancers with specific mutations in the SWI/SNF complex, ARID1A, ARID1B, SMARCA4, SMARCA2, cancers with mutations in specific oncogenes, EGFR, KRAS, RET, cancers with differential expression of certain genes, LAPTM5, RNASE6, IL-16, APOBEC3 and TYROBP, depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic lateral sclerosis, Dementia with lewy bodies, Frontotemporal dementia or MYC amplified tumor.

19. The use as claimed in claim 18, wherein the disease or condition is selected from multiple myeloma (MM), myeloproliferative neoplasms (MPN), polycythemia vera (PV), myeloproliferative dysplastic syndrome, essential thrombocythemia (ET), essential thrombocytosis or myelofibrosis (MF).

20. Use of the compound as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treatment and/or prevention of a disease or a condition.

21. Use of the compounds as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treatment of a disease or a condition mediated by LSD1 or HDAC or both LSD1 and HDAC or MYC or coREST, treatment and/or prevention of a proliferative disorder or cancer; or treatment of cancer optionally together with other clinically relevant cytotoxic agents or non-cytotoxic agents.

22. The use as claimed in claims 20 and 21, wherein the disease or condition is selected from breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, rectal cancer, esophagus cancer, duodenal cancer, tongue cancer, pharyngeal cancer, brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, liver cancer, liver metastasis, kidney cancer, bile duct cancer, uterine body cancer, cervical cancer, ovarian cancer, urinary bladder, skin cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma and leukemia including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), Myeloproliferative neoplasms (MPN), polycythemia vera (PV), myeloproliferative dysplastic syndrome, essential thrombocythemia (ET), essential thrombocytosis and myelofibrosis (MF), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), cancers with specific mutations in the SWI/SNF complex, ARID1A, ARID1B, SMARCA4, SMARCA2, cancers with mutations in specific oncogenes, EGFR, KRAS, RET, cancers with differential expression of certain genes, LAPTM5, RNASE6, IL-16, APOBEC3 and TYROBP, depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic lateral sclerosis, Dementia with lewy bodies, Frontotemporal dementia or MYC amplified tumor.

23. The use as claimed in claim 18, wherein the disease or condition is selected from small cell lung cancer (SCLC), gastric cancer, pancreatic cancer, lung cancer, liver metastasis and breast cancer.

24. The use as claimed in claim 18, wherein the cancer has RB1 mutation.

25. Use of the compound as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treating a subject with a tumor, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

26. The use as claimed in claim 25, wherein the tumor is a neuroendocrine tumor.

27. The use as claimed in claim 26, wherein the neuroendocrine tumor is a small cell lung cancer, neuroendocrine prostate cancer or MYC amplified tumor.

28. Use of the compound as claimed in any one of the claims 1 to 4 or the pharmaceutical composition as claimed in claim 8 or 9 in the manufacture of a medicament for treating a subject with cancer, wherein a therapeutically effective amount of the compound is to be administered to the subject.